Cell Therapy

Can Cell Therapy Overcome Manufacturing and Market Challenges?
Research & Development Can Cell Therapy Overcome Manufacturing and Market Challenges?

The field of cell therapy, initially heralded as a revolutionary frontier in biotechnology, is now grappling with considerable hurdles that threaten its progress and market penetration. Known for pioneering treatments like CAR-T cell therapy, which modifies a patient's T-cells to combat cancer more

Is PLX-R18 the Future of Nuclear Radiation Therapy?
Research & Development Is PLX-R18 the Future of Nuclear Radiation Therapy?

In the rapidly advancing field of nuclear radiation therapy, a groundbreaking treatment is emerging, promising to redefine the landscape of medical response to nuclear events. Financed by the backing of a weighty $4.2 million agreement with the National Institute of Allergy and Infectious Diseases

Unlocking Cancer's Foe: The Power of CD8-fit T Cells
Research & Development Unlocking Cancer's Foe: The Power of CD8-fit T Cells

Cancer treatments have long been a complex array of procedures with varying degrees of success. However, groundbreaking research from the University of Houston, spearheaded by Navin Varadarajan and his team, has shone a light on a new horizon for cancer therapy. They have identified CD8-fit T

How Will Sefia Revolutionize CAR-T Cell Therapy Production?
Management & Regulatory How Will Sefia Revolutionize CAR-T Cell Therapy Production?

The recent unveiling of the Sefia manufacturing platform by Cytiva, in partnership with Gilead Sciences’ Kite Pharma, marks a transformative step in the field of CAR-T cell therapy. With demand for these life-saving treatments increasing, the traditional production methods, fraught with manual

How Is Tech Shaping the Analytical Instrument Industry?
Research & Development How Is Tech Shaping the Analytical Instrument Industry?

The seamless integration of technology into the fabric of scientific research has brought about a seminal shift in the analytical instrument industry. Key industry players have long recognized that innovation is not just a buzzword but the fundamental driver of growth and efficiency in the lab.

S&P 500 Surge Signals Bright End; Biopharma Stocks Shine
Research & Development S&P 500 Surge Signals Bright End; Biopharma Stocks Shine

The financial markets have recently witnessed a significant uptick, particularly focusing on the robust performance of the S&P 500 index. With a history of early gains often translating into positive year-end outcomes, the current rise of over 10% within the first 100 trading days has set a hopeful

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later